Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2545–2568 of 13,632 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatologic Disorders Clear all

Conditions: Thyroid Cancer, Breast Cancer, Non-Melanoma Skin Cancer, Melanoma
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 6,093 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Melanoma
Interventions: Relatlimab, Ipilimumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: Tucson, Arizona • Los Angeles, California • Santa Monica, California + 4 more

Conditions: Breast Cancer, Gastric Cancer, Solid Tumors, NSCLC
Interventions: Pyrotinib; Drug
Lead sponsor: Hengrui Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 10
States / cities: Orange, California • Sacramento, California • Sarasota, Florida + 6 more

Conditions: Staphylococcal Skin Infection
Interventions: TD-1792, Vancomycin; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: National City, California

Conditions: Actinic Keratosis
Interventions: Lesion count; Drug
Lead sponsor: Peplin; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 38
States / cities: Hot Springs, Arizona • Fremont, California • Los Angeles, California + 35 more

Conditions: Dermatitis, Atopic
Interventions: MK-6194, Placebo; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 13
States / cities: North Little Rock, Arkansas • Miami, Florida • Miami Lakes, Florida + 9 more

Conditions: Melanoma
Interventions: Cobimetinib, Vemurafenib; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Insulin Resistance, NAFLD
Interventions: Caloric Restriction; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2034
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Melanoma, Malignant Melanoma, Melanoma, Experimental
Interventions: DMF5 Melanoma Reactive TIL, Cyclophosphamide, Fludarabine, Aldesleukin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: octreotide acetate, tamoxifen citrate; Drug
Lead sponsor: NCIC Clinical Trials Group; Network
Eligibility: Up to 120 Years · Female only
Enrollment: 667 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2010
U.S. locations: 2
States / cities: Duluth, Minnesota

Conditions: Breast Cancer (Locally Advanced or Metastatic), Lymphoma, Colorectal Cancer
Interventions: ASSIST phone application; Other
Lead sponsor: Patrick C. Johnson, MD; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Neoplasms
Interventions: General anesthesia and opioids, Regional analgesia and propofol; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 2,108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Breast Neoplasms
Interventions: High-Dose Chemo with Autologous BMT; Procedure
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2002
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Moderate to Severe Plaque-type Psoriasis
Interventions: Secukinumab (AIN457), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 28 more

Conditions: Breast Cancer
Interventions: Enzastaurin, Bevacizumab, Paclitaxel, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 7
States / cities: Newark, Delaware • Galesburg, Illinois • Fort Wayne, Indiana + 4 more

Conditions: Hidradenitis Suppurativa
Interventions: Verbal consultation, Written Action Plan; Behavioral
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 89 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: HIV Infections, Type 2 Diabetes, Obesity, HIV, AIDS, Cardiovascular Disease, Lipodystrophy
Interventions: Pioglitazone, Exercise training; Drug · Behavioral
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Psoriasis
Interventions: CEP-701 20mg, CEP-701 40mg, CEP-701 60mg, CEP-701 80mg; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 3
States / cities: Winston-Salem, North Carolina • Dallas, Texas • Norfolk, Virginia

Conditions: Hereditary Angioedema (HAE)
Interventions: Not listed
Lead sponsor: Shire; Industry
Eligibility: Not listed
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 23
States / cities: Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 20 more

Conditions: Acne
Interventions: Epiduo vehicle gel, CD07223, Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 9
States / cities: Hot Springs, Arkansas • Louisville, Kentucky • Warren, Michigan + 6 more

Conditions: Diabetic Foot Ulcer
Interventions: Folinic acid calcium salt; Combination Product
Lead sponsor: Joseph Boykin, MD; Federal
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Pressure Injury
Interventions: Mepilex Border Flex® (MBF) dressing; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Breast Carcinoma, Breast Cancer, Breast Cancer Female
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Soft Tissue Sarcoma, Renal Cell Carcinoma, Uterine Carcinosarcoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma
Interventions: HFB301001; Drug
Lead sponsor: HiFiBiO Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 7
States / cities: Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 4 more

Search by objective public record fields.

The Incidence of Breast and Other Cancers Among Female Flight Attendants

A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment

Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors

TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection

A Long Term Follow up Study of Patients Who Have Completed the PEP005-016 or PEP005-025 Studies

Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)

Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma

Reversal of Lipid-Induced Insulin Resistance

Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma

Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer

Remote Monitoring and Symptom Management Digital Application

Regional Anesthesia and Breast Cancer Recurrence

High Dose Chemo With Autologous BMT for Treatment of Metastatic Breast Cancer

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer

Evaluating the Effect of a Written Action Plan on Comfort and Understanding of Hidradenitis Suppurativa

Exercise and Pioglitazone for HIV-Metabolic Syndromes

Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe Psoriasis

A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America

Exploratory Study to Evaluate the Efficacy and Safety of CD07223 Gel in Subjects With Acne

Evaluation of a Folic Acid Wound Treatment (FAWT) for Chronic, Early-Stage Diabetic Foot Ulcer (DFU) Healing

Decreasing Intraoperative Skin Damage in Prone Position Surgeries

Exploring Cultural Acceptability of Community Breast Cancer Risk Assessment Among Hispanic Women in Maricopa County

A Study of HFB301001 in Adult Patients With Advanced Solid Tumors